Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time and will be accessible live via Vanda's website under the Investors tab.

Investors are advised to register at the conference site at least 15 minutes early to download required software; an archived link will be available on Vanda's site for approximately 30 days.

Key Figures

Conference date: March 11, 2026 Presentation time: 2:15 p.m. ET Archive duration: 30 days +1 more

4 metrics

Conference date March 11, 2026 Citizens Life Sciences Conference participation

Presentation time 2:15 p.m. ET Scheduled corporate presentation slot

Archive duration 30 days Length of archived conference webcast availability

Early login 15 minutes Suggested early arrival to register and install software

Market Reality Check

Price: $8.28 Vol: Volume 2,214,991 is below...

low vol

$8.28 Last Close

Volume Volume 2,214,991 is below the 4,265,340 20-day average, suggesting muted trading interest. low

Technical Shares at $8.60 are trading above the 200-day MA of $5.40, indicating a pre-existing uptrend.

Peers on Argus

VNDA was up 1.35% pre-news. Among close peers, moves were mixed: NMRA (+1.43%), ...

1 Up

VNDA was up 1.35% pre-news. Among close peers, moves were mixed: NMRA (+1.43%), OMER (+1.49%), CADL (-0.58%), TNXP (-2.57%), LXEO (+0.15%). Momentum scanner only flagged MNPR (+1.99%), suggesting no broad, synchronized sector move.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	BLA acceptance	Positive	+1.4%	FDA accepted imsidolimab BLA for treating generalized pustular psoriasis.
Feb 20	FDA approval	Positive	+41.5%	FDA approved BYSANTI for bipolar I disorder and schizophrenia in adults.
Feb 11	Earnings results	Negative	-17.6%	2025 results showed revenue growth but a large net loss and tax allowance.
Feb 04	Earnings date	Neutral	-4.9%	Company scheduled Q4 and full-year 2025 results release and call details.
Jan 08	Regulatory setback	Negative	-14.1%	FDA said HETLIOZ sNDA for jet lag disorder cannot be approved as submitted.

Pattern Detected

Recent VNDA news shows price generally tracking the tone of fundamental FDA and earnings events, with mostly aligned reactions to both positive approvals and negative regulatory outcomes.

Recent Company History

Over the last few months, Vanda has reported several major milestones. On Feb 20, 2026, the FDA approved BYSANTI (milsaperidone), driving a 41.49% gain. On Feb 25, 2026, the FDA accepted the BLA for imsidolimab in GPP, with shares up 1.35%. Earlier, full-year 2025 results on Feb 11 highlighted $216.1M in revenue but a $220.5M net loss, followed by a -17.63% move. A negative FDA decision letter on HETLIOZ sNDA on Jan 8 coincided with a -14.05% decline.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2026-02-12

$200,000,000 registered capacity

An effective S-3 shelf filed on Feb 12, 2026 allows Vanda to offer up to $200,000,000 of securities over time for general corporate purposes, though no usage has been reported yet.

Market Pulse Summary

This announcement outlines Vanda’s corporate presentation at the Citizens Life Sciences Conference o...

Analysis

This announcement outlines Vanda’s corporate presentation at the Citizens Life Sciences Conference on March 11, 2026 at 2:15 p.m. ET, with the webcast archived for 30 days. It follows a series of impactful FDA developments and earnings disclosures in early 2026. Investors may track how management frames recent approvals, the imsidolimab BLA, and capital flexibility under the $200,000,000 shelf, along with any updated commentary on commercialization timelines and strategic priorities.

AI-generated analysis. Not financial advice.

WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time.

The corporate presentation given at the Citizens Life Sciences Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-in-the-2026-citizens-life-sciences-conference-302699013.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

When will Vanda (VNDA) present at the Citizens Life Sciences Conference?

Vanda (VNDA) will present on March 11, 2026 at 2:15 p.m. Eastern Time. According to the company, the corporate presentation is scheduled for that date and will be streamed live on Vanda's corporate website with an archived link available for about 30 days.

How can investors watch the VNDA corporate presentation live on March 11, 2026?

Investors can watch live on Vanda's corporate website via the Investors tab. According to the company, a webcast link will be posted under Recent Events and the presentation may also be accessed through the conference platform with prior registration.

How long will the archived VNDA presentation be available after the March 11, 2026 conference?

The archived presentation will be available for approximately 30 days after the conference. According to the company, investors can access the archived link on Vanda's website under Recent Events during that roughly 30-day period for on-demand viewing.

Do investors need to register or install software to view Vanda (VNDA) at the conference?

Yes, investors should register and may need to install software before the event. According to the company, attendees are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations.

Will Vanda (VNDA) release financial results during the March 11, 2026 presentation?

The announcement does not specify whether financial results will be released during the presentation. According to the company, the event is described as a corporate presentation without detailing specific content such as earnings or clinical updates.

Where will the replay of Vanda's (VNDA) Citizens conference presentation be posted?

The replay will be posted on Vanda's corporate website under the Investors tab. According to the company, a link to the archived conference will be available on the company's site for approximately 30 days following the live presentation.